1. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. 2021;102:501–8.
2. Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 2021;21:489.
3. Aung KZL, Yılmaz R, Güngördü E, Aşar S, Tekdos Şeker Y. Does Favipiravir Reduce Mortality in Patients with COVID-19 ARDS and Severe Pneumonia? Turk. J. Intensive Care 2021;19:102–9.
4. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrob. Agents Chemother. 2020;64:e01897-20.
5. Bosaeed M, Alharbi A, Mahmoud E, Alrehily S, Bahlaq M, Gaifer Z, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin Microbiol Infect. 2022 Apr;28(4):602-608.
6. Shinkai M, Tsushima K, Tanaka S, Hagiwara E, Tarumoto N, Kawada I, et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect. Dis. Ther. 2021;10:2489–509.
7. Al-Muhsen S, Al-Numair NS, Saheb Sharif-Askari N, Basamh R, Alyounes B, Jabaan A, et al. Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia. Front. Med. 2022;9:826247.
8. Almoosa Z, Saad M, Qara S, Mustafa M, Mansour A, Alshab D, et al. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. J. Infect. Public Health 2021;14:1247–53.
9. Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int. Immunopharmacol. 2021;95:107522.
10. Özlüşen B, Kozan Ş, Akcan RE, Kalender M, Yaprak D, Peltek İB, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2021;40:2575–83.
11. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J. Virus Erad. 6:45–51.
12. Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: A Simplified Summary. Drug Res. 2021;71:166–70.
13. Tırmıkçıoğlu Z. Favipiravir exposure and pregnancy outcome of COVID-19 patients. Eur. J. Obstet. Gynecol. Reprod. Biol. 2022;268:110–5.
14. World Health Organization. Therapeutics and COVID-19 Living Guideline. WHO. 2022 Jan 14. https://apps.who.int/iris/bitstream/handle/10665/351006/WHO-2019-nCoV-therapeutics-2022.1-eng.pdf